Portal Hypertension Portal hypertension is an increase in the blood pressure within a system of veins called the portal venous system. The increase in pressure is caused by a blockage in the blood flow through the liver. Symptoms include ascites, reduced levels of platelets or white blood cells, gastrointestinal bleeding, encephalopathy or confusion and forgetfulness. The most common cause of portal hypertension is cirrhosis or scarring of the liver.
Portal Hypertension pipeline therapeutics constitutes close to 6 molecules. Out of which approximately 6 molecules are developed by Companies. The molecules developed by Companies in Phase II, Phase I and Preclinical stages are 4, 1 and 1 respectively.
Portal Hypertension - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Portal Hypertension and features dormant and discontinued projects.
Key Topics Covered:
- Portal Hypertension Overview
- Therapeutics Development
- Pipeline Products for Portal Hypertension - Overview
- Pipeline Products for Portal Hypertension - Comparative Analysis
- Portal Hypertension - Therapeutics under Development by Companies
- Portal Hypertension - Therapeutics under Investigation by Universities/Institutes
- Portal Hypertension Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Portal Hypertension - Products under Development by Companies
- Portal Hypertension - Products under Investigation by Universities/Institutes
- Portal Hypertension - Companies Involved in Therapeutics Development
- Conatus Pharmaceuticals Inc.
- Cumberland Pharmaceuticals, Inc.
- Galectin Therapeutics, Inc.
- Genextra S.p.a.
- LinXis B.V.
- Mezzion Pharma Co. Ltd.
For more information about this report visit http://www.researchandmarkets.com/research/hzg7mq/portal